Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to ...
Viking Therapeutics faces tough competition in the obesity drug market dominated by Eli Lilly and Novo Nordisk, with first-mover advantages hard to overcome. VK2735 shows promising early efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback